Ofatumumab
Active ingredient · 2 therapeutic classes
Sold as Arzerra · KESIMPTA
- Drug class
- Cd20 (Clusters Of Differentiation 20) Inhibitors
- Availability
- See label
- Routes
- Subcutaneous
- Markets covered
- 3
- Products on record
- 7
Overview
Ofatumumab is an active pharmaceutical ingredient in the Cd20 (Clusters Of Differentiation 20) Inhibitors group (L01FA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | May 15, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
| EU European Union | EMA | 1 | February 5, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
1).
How to take
CACanada· Health Canada
2 products
Uses
KESIMPTA® (ofatumumab injection) is indicated for: • the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features (see 14 CLINICAL TRIALS). Kesimpta treatment should be initiated and supervised by health professionals experienced in the treatment of patients with MS and who are familiar with the efficacy and safety profile of Kesimpta (see 7 WARNINGS AND PRECAUTIONS).
1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of Kesimpta in pediatric MS patients below the age of (<18 years of age) have not been studied. Kesimpta is not authorized for pediatric use. 2 Geriatrics Geriatrics: Ofatumumab was not studied in patients ≥ 55 years of age.
How to take
EUEuropean Union· EMA
1 product
Uses
1).
How to take
Drug interactions
Known interactions involving Ofatumumab. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB001011201 · revised May 15, 2026
- [2]Health Canada (DPD) · 02511355 · revised March 22, 2025
- [3]European Medicines Agency · EMEA/H/C/005410 · revised February 5, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.